Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 plus nab-paclitaxel versus placebo plus nab-paclitaxel as first-line treatment for PD-L1-negative unresectable locally advanced or metastatic triple-negative breast cancer
CTR20250033Phase 3Active
- Sponsor
- Akeso, Inc.
- Start
- Feb 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ivonescimab in triple-negative breast cancer (TNBC), sponsored by Akeso, Inc.. Started Feb 2025; status: active.
02
Drugs
ivonescimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20250033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250033.